Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

The Finviz API:   Higher Limits, Clearer Data, and More Ways to Connect

Get Started Now
Market News Market Pulse Stocks News ETF News Crypto News

Aardvark Therapeutics, Inc.

Contributing Author

Recent Articles by Aardvark Therapeutics, Inc.

Oct-08
Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors AARD -5.04% GlobeNewswire
Oct-02
Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) AARD -5.31% GlobeNewswire
Aug-11
Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates AARD AARD -8.62% GlobeNewswire
May-14
Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold AARD AARD -32.10% GlobeNewswire
May-07
Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates AARD GlobeNewswire
Mar-23
Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates AARD AARD -7.26% GlobeNewswire
Feb-27
Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome AARD AARD -56.20% GlobeNewswire
Feb-13
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) AARD GlobeNewswire
Feb-12
Aardvark Therapeutics Announces Leadership Appointments AARD GlobeNewswire
Feb-12
Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer AARD GlobeNewswire
Feb-10
Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome AARD -6.45% GlobeNewswire
Dec-10
Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome AARD AARD +11.66% GlobeNewswire
Nov-25
Aardvark Therapeutics to Present at Upcoming Investor Conferences in December AARD GlobeNewswire
Nov-13
Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates AARD AARD -8.66% GlobeNewswire
Nov-11
Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) AARD +5.94% GlobeNewswire
Nov-04
Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025 AARD -5.68% AARD +7.14% GlobeNewswire
Nov-03
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) AARD GlobeNewswire
Nov-03
Aardvark Therapeutics to Present at Upcoming Investor Conferences in November AARD GlobeNewswire
Oct-22
Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek AARD -8.28% GlobeNewswire
Oct-08
Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome AARD GlobeNewswire
Sep-23
Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum AARD AARD +6.38% GlobeNewswire
Sep-04
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) AARD GlobeNewswire
Aug-27
Aardvark Therapeutics to Present at Upcoming Investor Conferences in September AARD -5.67% AARD -5.56% GlobeNewswire
Aug-13
Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates AARD +11.55% GlobeNewswire
Aug-12
Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy AARD -9.96% GlobeNewswire
Jul-18
Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) AARD GlobeNewswire
Jun-24
Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference AARD +18.23% GlobeNewswire
May-19
Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions AARD +5.46% AARD +5.47% GlobeNewswire
May-14
Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights AARD -13.81% GlobeNewswire
May-07
Aardvark Therapeutics to Present at Upcoming Investor Conferences in May AARD GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)